Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression
- Sandra Heskamp
- ,
- Otto C. Boerman
- ,
- Janneke D. M. Molkenboer-Kuenen
- ,
- Fred C. G. J. Sweep
- ,
- Anneke Geurts-Moespot
- ,
- Mallory S. Engelhardt
- ,
- Winette T. A. van der Graaf
- ,
- Wim J. G. Oyen
- , and
- Hanneke W. M. van Laarhoven
Abstract
Bevacizumab and cetuximab are approved for the treatment of cancer. However, in advanced colorectal cancer, addition of cetuximab to chemotherapy with bevacizumab did not improve survival. The reason for the lack of activity remains unclear. The aim of this study was to determine the effect of cetuximab on VEGF expression and targeting of bevacizumab to the tumor. Mice with subcutaneous SUM149 or WiDr xenografts were treated with cetuximab, bevacizumab, or a combination of the two. Before the start of cetuximab treatment and after 7 and 21 days of treatment, the uptake of radiolabeled bevacizumab in the tumor was measured by immunoSPECT/CT. Tumor growth of SUM149 xenografts was significantly inhibited by cetuximab, bevacizumab, or their combination, whereas growth of WiDr xenografts was not affected. Cetuximab caused a significant reduction of bevacizumab uptake in SUM149 xenografts, whereas tumor-to-blood ratios in mice with WiDr xenografts did not change. Biodistribution studies with an irrelevant antibody in the SUM149 model also showed significantly reduced tumor-to-blood ratios. Cetuximab treatment did not decrease VEGF expression. Without decreasing VEGF levels, cetuximab reduces tumor targeting of bevacizumab. This could, at least partly, explain why the combination of bevacizumab and cetuximab does not result in improved therapeutic efficacy.
Cited By
This article is cited by 8 publications.
- Kewen Qian, Wenyan Fu, Changhai Lei, Shi Hu. Dual inhibition of EGFR and c-Src by cetuximab and dasatinib combined with FOLFOX chemotherapy in patients with metastatic colorectal cancer. 2023, 99-103. https://doi.org/10.1016/B978-0-12-821584-5.00028-6
- Christel Larbouret, Laurent Gros, André Pèlegrin, Thierry Chardès. Improving Biologics’ Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures. Cancers 2021, 13
(18)
, 4620. https://doi.org/10.3390/cancers13184620
- Ming Qi, Shufeng Gao, Sihui Nie, Ke Wang, Lingling Guo. Precise engineering of cetuximab encapsulated gadollium nanoassemblies:
in vitro
ultrasound diagnosis and
in vivo
thyroid cancer therapy. Drug Delivery 2021, 28
(1)
, 569-579. https://doi.org/10.1080/10717544.2021.1889721
- Christel Larbouret, Marie-Alix Poul, Thierry Chardès. Imiter la réponse immunitaire humorale polyclonale. médecine/sciences 2019, 35
(12)
, 1083-1091. https://doi.org/10.1051/medsci/2019216
- Katja Zirlik, Justus Duyster. Combination of Anti-angiogenics and Other Targeted Therapies. 2019, 359-376. https://doi.org/10.1007/978-3-319-33673-2_14
- Run Lin, Jing Huang, Liya Wang, Yuancheng Li, Malgorzata Lipowska, Hui Wu, Jianyong Yang, Hui Mao. Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging. Biomaterials Science 2018, 6
(6)
, 1517-1525. https://doi.org/10.1039/C8BM00225H
- Katja Zirlik, Justus Duyster. Combination of Antiangiogenics and Other Targeted Therapies. 2017, 1-18. https://doi.org/10.1007/978-3-319-31215-6_14-1
- Linda M. Henricks, Jan H.M. Schellens, Alwin D.R. Huitema, Jos H. Beijnen. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews 2015, 41
(10)
, 859-867. https://doi.org/10.1016/j.ctrv.2015.10.008